Merck (ETR:MRK) Stock Upgrade
In a recent report distributed on Thursday morning, Norddeutsche Landesbank announced that they have decided to upgrade Merck (ETR:MRK) shares to a Buy.
From a total of 18 analysts covering Merck (ETR:MRK) stock, 8 rate it a ”Buy”, 0 a “Sell”, and 11 a ”Hold”. This means that 42% of the ratings are positive. The highest target price is €72 while the lowest target price is €54. The mean of all analyst targets is €62.56 with a 1.32% above today’s (€96.73) stock price. Merck was the topic of 24 analyst reports since August 4, 2015 according to the firm StockzIntelligence Inc. JP Morgan maintained shares on December 1 with “Neutral” rating. BNP Paribas upgraded shares to “Outperform” rating and €107 target share price in a report from an October 22. Societe Generale maintained MRK stock in a recent report from November 14 with “Hold” rating. Baader Wertpapierhandelsbank maintained the rating on October 15. Baader Wertpapierhandelsbank has a “Hold” rating and a €96 price target on shares. Finally, UBS maintained the stock with “Neutral” rating in a report issued on a November 11.
The stock increased 0.58% or EUR 0.56 on December 2, striking EUR 96.73. Approximately 350,180 shares of stock traded hands. Merck KGaA (ETR:MRK) has declined 9.64% since April 30, 2015 and is downtrending. It has underperformed by 9.44% the S&P500.
Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The company has a market cap of 12.50 billion EUR. The Firm diversifies its activities into four business divisions: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. It has 33.14 P/E ratio. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin.
According to Zacks Investment Research, “Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.” Get a free copy of the Zacks research report on Merck KGaA (MRK).